Cargando…

Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model

BACKGROUND: Urosepsis caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli is increasing worldwide. Carbapenems are commonly recommended for the treatment of ESBL infections; however, to minimize the emergence of carbapenem resistance, interest in alternative treatments has heig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Islam, Kamrul, Sime, Fekade B, Wallis, Steven C, Bauer, Michelle J, Forde, Brian M, Harris, Patrick, Shirin, Tahmina, Habib, Zakir H, Flora, Meerjady S, Roberts, Jason A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9410668/ https://www.ncbi.nlm.nih.gov/pubmed/35724128 http://dx.doi.org/10.1093/jac/dkac186

Ejemplares similares

Meropenem/piperacillin/tazobactam: Drug resistance: case report
Publicado: (2021)

486 Meropenem and Piperacillin-tazobactam have Comparable Outcomes in Treatment of Bloodstream Infections Caused by Extended Spectrum Beta-lactamase Producing E.coli and Klebsiellae
por: Harris, Patrick, et al.
Publicado: (2014)

Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae
por: Zhang, Wei, et al.
Publicado: (2023)

182. Piperacillin/tazobactam (P/T) versus meropenem (Mero) for treatment of extended-spectrum beta-lactamase (ESBL)-producing E.coli and K. pneumoniae bloodstream infections (BSIs)
por: Cox, Alexandra L, et al.
Publicado: (2023)

2746. Assessment of in vitro synergy between Piperacillin-Tazobactam-Meropenem and Imipenem-Meropenem against OXA-48 Producing Klebsiella pneumoniae Using Time-Kill Assays
por: Demir, Mervenur, et al.
Publicado: (2023)

1292. Evaluation of Synergy with Piperacillin/Tazobactam plus Meropenem Against Carbapenemase-Producing Klebsiella pneumoniae and Enterobacter cloacae Using ETEST
por: Ashcraft, Deborah S, et al.
Publicado: (2021)

Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients
por: Heil, Emily, et al.
Publicado: (2017)

Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
por: Ng, Tat Ming, et al.
Publicado: (2016)

Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs
por: Barber, Katie E., et al.
Publicado: (2016)

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
por: Carlier, Mieke, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients
por: Veillette, John J., et al.
Publicado: (2021)

Comparison of Acute Kidney Injury During Treatment with Vancomycin and either Piperacillin-Tazobactam or Meropenem
por: Cannon, John M., et al.
Publicado: (2017)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
por: Berrino, Pasquale Maria, et al.
Publicado: (2023)

Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)
por: Stewart, Adam G, et al.
Publicado: (2021)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Comparison of Rates of Acute Kidney Injury with Vancomycin/Piperacillin-Tazobactam vs. Vancomycin/Meropenem Combination Therapy
por: Pernia, Sonia, et al.
Publicado: (2017)

Piperacillin/Tazobactam and Meropenem Use Increases the Risks for Acute Graft Rejection Following First Kidney Transplantation
por: Nasr, Dayana, et al.
Publicado: (2022)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase–producing Enterobacterales bloodstream infections (REDUCE-BSI)
por: Vu, Catherine H., et al.
Publicado: (2022)

Pragmatic Comparison of Piperacillin/Tazobactam versus Carbapenems in Treating Patients with Nosocomial Pneumonia Caused by Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae
por: Zha, Lei, et al.
Publicado: (2022)

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model
por: Avent, Minyon L., et al.
Publicado: (2022)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Drug-induced hypersensitivity syndrome with high procalcitonin levels due to piperacillin/tazobactam and meropenem: A case report
por: Song, Gao, et al.
Publicado: (2022)

Piperacillin-tazobactam vs. carbapenem for treating blood stream infections due to extended spectrum β-lactamase producing bacteria: Systematic review and meta-analysis
por: Sfeir, Maroun, et al.
Publicado: (2017)

Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli
por: Seo, Yu Bin, et al.
Publicado: (2017)

Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model
por: Mohd Sazlly Lim, Sazlyna, et al.
Publicado: (2022)

Early Treatment Outcomes for Bloodstream Infections Caused by Potential AmpC Beta-Lactamase-Producing Enterobacterales with Focus on Piperacillin/Tazobactam: A Retrospective Cohort Study
por: Herrmann, Lena, et al.
Publicado: (2021)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

2775. Clinical Outcomes and Treatment-Emergent Resistance of Piperacillin-tazobactam, Cefepime, Carbapenems and Fluoroquinolones for the Treatment of Bloodstream Infections due to AmpC β-Lactamase-Producing Enterobacterales
por: Jawanda, Jasanjeet, et al.
Publicado: (2023)

1436. Comparison of Ceftazidime–Avibactam, Ceftolozane–Tazobactam, Piperacillin–Tazobactam, and Meropenem Activities When Tested Against Gram-Negative Organisms Isolated From Complicated Urinary Tract Infections
por: Sader, Helio S, et al.
Publicado: (2019)

Enterobacter endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
por: Singh, Trehan Hemant, et al.
Publicado: (2007)

Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017)

Piperacillin/tazobactam: Eosinophilic-pneumonia: case report
Publicado: (2021)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

1411. Tecioplanin (TEI) vs. Vancomycin (VAN) in Combination with Piperacillin-Tazobactam (TZP) or Meropenem (MER) as a Cause of Acute Kidney Injury (AKI)
por: Aslan, Abdullah Tarik, et al.
Publicado: (2018)

Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Simulation of Piperacillin/Tazobactam for Dosing Optimization in Late Elderly Patients with Pneumonia
por: Ishihara, Noriyuki, et al.
Publicado: (2020)

Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
por: Felton, T W, et al.
Publicado: (2014)

Tazobactam and piperacillin-induced thrombocytopenia: A case report
por: CHEN, HONG, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_aqv05sv0hgj0rdmfq9o5draept